What is the Opioid Crisis in Canada?
Canada’s opioid crisis — formally designated by the federal government and all provincial and territorial health authorities as a national public health emergency — is the sustained mass poisoning of the Canadian population by a toxic, unregulated illegal drug supply contaminated with synthetic opioids and an increasingly complex mixture of other substances. It is not, despite common framing, a crisis of addiction alone. The overwhelming majority of the deaths it produces are accidental: 96% of opioid toxicity deaths in Canada in 2025 were unintentional, according to the Public Health Agency of Canada (PHAC). People who use drugs — and, increasingly, people who do not primarily use opioids but encounter contaminated stimulants, counterfeit pills, or adulterated street drugs — are dying because the illegal drug supply has been transformed by the introduction of synthetic opioids that are lethal in quantities invisible to the naked eye. The crisis began gaining national visibility when British Columbia declared a provincial public health emergency in April 2016, and it has since claimed more than 55,000 lives across the country — a toll that has made opioid toxicity the leading cause of accidental death among Canadians in their prime working years. The PHAC’s surveillance infrastructure, continuously updated through the Canadian Coroner and Medical Examiner Database (CCMED), the Discharge Abstract Database, the National Ambulatory Care Reporting System (NACRS), and provincial EMS reporting systems, provides one of the most granular national drug crisis datasets of any country in the world.
What distinguishes Canada’s opioid crisis from the US crisis — with which it shares drug supply chains, policy tensions, and many epidemiological features — is the specific character of its drug supply and its geographic pattern. Canada’s crisis has been overwhelmingly driven by illegal, non-pharmaceutical opioids (81% of 2025 deaths involve non-pharmaceutical substances), is disproportionately concentrated in Western Canada (BC, Alberta, and Ontario together account for 78% of 2025 opioid toxicity deaths), and has produced a death toll that, while declining from its 2023 peak of 8,623 deaths, remains nearly double its pre-pandemic 2019 level of 3,742. The 2026 picture is one of a crisis entering a new and complicated phase: deaths have declined, driven by a partial reduction in drug supply toxicity, expanded naloxone distribution, and increased opioid agonist therapy (OAT) access — but new threats including nitazenes, xylazine, medetomidine, and the continued prevalence of stimulant co-poisoning (present in 70% of 2025 opioid deaths) are reshaping the crisis in ways that existing harm reduction tools address only partially. The data sources used throughout this article are exclusively PHAC, Health Canada, the Canadian Centre on Substance Use and Addiction (CCSA), the Canadian Institute for Health Information (CIHI), and verified government publications.
Key Facts: Canada Opioid Crisis Statistics 2026
The following table captures the most essential and current Canada opioid crisis facts 2026 — drawn from PHAC’s opioid and stimulant-related harms surveillance dashboard (updated March 25, 2026), Health Canada’s federal actions overview, and the Council of Chief Medical Officers of Health Statement (December 11, 2025).
| Key Fact | Verified Stat |
|---|---|
| Total cumulative opioid toxicity deaths (Jan 2016 – Sep 2025) | 55,032 apparent opioid toxicity deaths |
| Total cumulative opioid poisoning hospitalizations (2016–Sep 2025) | 51,563 opioid-related poisoning hospitalizations |
| Total opioid toxicity deaths — full year 2024 | 7,146 deaths — down 17% from 2023 peak |
| Total opioid toxicity deaths — full year 2023 (peak) | 8,623 deaths — all-time high |
| Total opioid toxicity deaths — full year 2019 (pre-pandemic) | 3,742 deaths — 2024 still nearly double this |
| Opioid toxicity deaths January–September 2025 | 4,162 deaths — 96% accidental |
| Average daily opioid deaths in Canada — 2024 | ~20 Canadians per day |
| Share of Jan–Sep 2025 deaths involving non-pharmaceutical opioids | 81% — illegal street drugs |
| Share of Jan–Sep 2025 deaths also involving a stimulant | 70% — polysubstance crisis |
| Share of Jan–Sep 2025 deaths involving fentanyl | 58% (down from 74% in 2024) |
| Share of Jan–Sep 2025 deaths involving fentanyl analogues | 57% — growing role |
| Provinces with 78% of 2025 opioid deaths (Jan–Sep) | British Columbia, Alberta, and Ontario |
| Per-capita provinces with ≥20 deaths per 100,000 (2024) | Yukon, Alberta, and Manitoba |
| Age group most affected — Jan–Sep 2025 | Ages 30–39: 26% of deaths; Ages 40–49: 25% |
| Gender — Jan–Sep 2025 opioid toxicity deaths | 74% male; 26% female |
| Leading cause of accidental death (2024 — confirmed by Statistics Canada) | Opioid poisoning for males aged 20–49; females aged 20–39 |
| Opioid poisoning hospitalizations — Jan–Sep 2025 | 3,613 hospitalizations — 69% accidental |
| Hospitalization gender breakdown — Jan–Sep 2025 | 58% male; 42% female (narrower gender gap than deaths) |
| Oldest age group overrepresented in hospitalizations | Ages 60+: 27% of hospitalizations (Jan–Sep 2025) |
| Fentanyl share of hospitalizations — Jan–Sep 2025 | 24% involved fentanyl or analogues |
| EMS responses to suspected opioid overdoses — full year 2024 | 36,266 responses — down ~15% from 2023 |
| Emergency department visits — full year 2024 | 24,587 ED visits — down ~15% from 2023 |
| First Nations people in Ontario: opioid death rate vs. non-First Nations (2022) | 9× higher — 12.8 vs 1.4 per 10,000 (Chiefs of Ontario / ODRPN, Oct 2025) |
| Indigenous people: risk of opioid-related harm vs. non-Indigenous | Up to 6× more likely (First Nations Health Authority, 2024) |
| Federal government total healthcare/substance use commitment | $25 billion through Working Together for Health Care agreements |
| Substance Use and Addiction Program (SUAP) investment (since 2017) | $758 million+ across 465+ community pilot projects |
Data Sources: Public Health Agency of Canada (PHAC) — “Key Findings: Opioid- and Stimulant-related Harms in Canada” (health-infobase.canada.ca, updated March 25, 2026); PHAC — “Decline in Opioid-related Deaths in Canada” (December 11, 2025); Council of Chief Medical Officers of Health — Statement on Latest National Data (December 11, 2025, canada.ca); Health Canada — “Federal Actions on the Overdose Crisis” (canada.ca, accessed May 2026); CBC News — “Overdose Deaths in Canada Fell in 2024” (June 25, 2025); GlobalNews — “Opioid Deaths in Canada Fell 17%” (June 25, 2025); Chiefs of Ontario / Ontario Drug Policy Research Network — “First Nations People in Ontario Disproportionately Affected by Opioid Crisis” (October 6, 2025); Canadian Public Health Association — Toxic Drug Crisis page (cpha.ca, citing FNHA 2024)
These 26 statistics frame Canada’s opioid crisis in its full scope — not just the deaths, but the cascade of harms extending through hospitalizations, emergency department visits, EMS responses, and deeply inequitable impacts on Indigenous communities. The 55,032 cumulative deaths since 2016 and 51,563 cumulative hospitalizations are both surveillance underestimates: PHAC is explicit that data for the most recent quarters is preliminary and will be revised upward, and that some provinces and territories — most notably Quebec for hospitalizations — are excluded from certain datasets due to reporting system differences. The 70% of 2025 opioid toxicity deaths that also involved a stimulant (cocaine, methamphetamine, amphetamines) is one of the most clinically significant developments in the crisis: it means the standard framing of “opioid overdose” as the primary mechanism of death is increasingly incomplete, and that a substantial and growing proportion of deaths involve simultaneous opioid and stimulant toxicity — a combination that creates unique cardiovascular and respiratory failure pathways that respond differently to naloxone and other reversal interventions.
Canada Opioid Crisis Death Trends 2016–2026
Apparent Opioid Toxicity Deaths in Canada — Full Annual Trend
(PHAC Surveillance Dashboard; updated March 25, 2026)
2016 |████████████████████████████ 2,861
2017 |████████████████████████████████████████ 3,987 (+39%)
2018 |████████████████████████████████████████████ 4,398 (+10%)
2019 |████████████████████████████████████ 3,742 (−15%) ← Pre-pandemic baseline
2020 |█████████████████████████████████████████████████ 6,214 (+66%) ← COVID-19 pandemic surge
2021 |████████████████████████████████████████████████████ 7,560 (+22%)
2022 |███████████████████████████████████████████████████ 7,328 (−3%)
2023 |█████████████████████████████████████████████████████ 8,623 (+18%) ← ALL-TIME PEAK
2024 |████████████████████████████████████████████████ 7,146 (−17%) ← First meaningful decline
2025*|████████████████████████████████████████ ~5,500 (projected; Jan–Sep = 4,162)
──────────────────────────────────────────────────────────────────────────────────────
0 2,000 4,000 6,000 8,000 8,623
*2025 full-year projected from Jan–Sep PHAC data; 96% of 4,162 accidental
Cumulative total Jan 2016 – Sep 2025: 55,032 deaths
| Year | Opioid Deaths | Change | Avg per Day | Key Development |
|---|---|---|---|---|
| 2016 | 2,861 | Baseline | 8/day | BC declares PHE; fentanyl enters supply nationally |
| 2017 | 3,987 | +39% | 11/day | Fentanyl dominates western street supply |
| 2018 | 4,398 | +10% | 12/day | National crisis acknowledged federally |
| 2019 | 3,742 | −15% | 10/day | Pre-pandemic low; brief decline |
| 2020 | 6,214 | +66% | 17/day | COVID-19: isolation, supply disruption, service gaps |
| 2021 | 7,560 | +22% | 21/day | Fentanyl analogues peak; carfentanil detections rise |
| 2022 | 7,328 | −3% | 20/day | Marginal decline; benzodiazepine mixing rises |
| 2023 | 8,623 | +18% | 24/day | All-time peak; fentanyl + stimulant combo dominant |
| 2024 | 7,146 | −17% | 20/day | First significant decline; supply toxicity falls |
| Jan–Sep 2025 | 4,162 | Continued decline | ~15/day | Naloxone effect; youth attitude shift; supply changes |
| Cumulative 2016–Sep 2025 | 55,032 | — | — | — |
Data Sources: PHAC — Key Findings: Opioid- and Stimulant-related Harms in Canada (health-infobase.canada.ca, March 25, 2026); CBC News — “Opioid deaths in Canada fell 17%” (August 21, 2025); GlobalNews — June 25, 2025; PHAC — Decline in Opioid-related Deaths (December 11, 2025); Council of Chief Medical Officers of Health Statement (December 11, 2025)
The death trend from 2016 to 2026 is a decade-long chronicle of escalation, pandemic shock, fragile recovery, and the complex interplay between supply toxicity, harm reduction capacity, and individual behaviour change. The 2019 pre-pandemic decline from 4,398 to 3,742 deaths provided a brief moment of optimism — attributed at the time to moderate reductions in fentanyl street toxicity and the gradual expansion of harm reduction services. That optimism was obliterated by COVID-19: the 2020 surge of +66%, adding 2,472 deaths in a single year, was the largest proportional year-over-year increase in the entire surveillance series and was directly attributed to pandemic-specific factors. Supervised consumption sites operated at reduced capacity due to distancing requirements. Drug supply chains disrupted at the border increased the variability and concentration of available substances. Isolation removed the social safety net — the presence of a friend, family member, or bystander who could call for help — that had been preventing countless deaths. And the psychological distress of lockdown, economic precarity, and social disconnection intensified drug use across multiple population segments.
The recovery from the 2023 peak of 8,623 deaths has been more sustained than many public health analysts anticipated. The Council of Chief Medical Officers of Health, in their December 2025 statement, identified seven potential drivers of the 2024 decline, three of which they designated as “likely” contributors: changes in the illegal drug supply (reduced fentanyl concentration, less benzodiazepine mixing), increased naloxone availability and use (with an Alberta study finding 23.9% reduction in deaths for every 10,000 naloxone kits distributed), and a reduction in the number of people at high risk. That last factor carries a painful dual explanation: partly, fewer young people are using opioids, driven by a genuine attitude shift among youth documented through people with lived experience; and partly, the “widespread loss of lives” among the highest-risk populations has itself reduced the at-risk denominator. The 2025 Jan–Sep data of 4,162 deaths projects to a full-year figure significantly below 2024 if sustained — but hospitalizations and EMS responses stabilized in the first half of 2025 rather than continuing to decline, signalling that the improvement in deaths may not be matched by an equivalent reduction in near-fatal overdose events.
Canada Opioid Crisis by Province — Deaths and Per-Capita Rates 2026
Opioid Toxicity Deaths — Provincial Geographic Pattern 2024–2025
(PHAC; 2024 annual data; Jan–Sep 2025 share data)
78% of Jan–Sep 2025 opioid toxicity deaths: BC + Alberta + Ontario
Per-Capita Death Rate ≥20 per 100,000 population (2024 PHAC data):
Yukon |████████████████████████████████████████████████████████ HIGHEST per capita
Alberta |████████████████████████████████████████████████████ ≥20 per 100,000
Manitoba |████████████████████████████████████████████████ ≥20 per 100,000
Provincial Year-over-Year Death Change (2023→2024 PHAC data):
British Columbia: ↓ Decreased
Alberta: ↓ Decreased
Ontario: ↓ 17% decrease (preliminary Chief Coroner data)
Manitoba: ~No significant change (data with caution)
Saskatchewan: Trends noted; part of national picture
Quebec: ↓ Began to decrease; previously rising
| Province / Territory | Share of 2025 Deaths (Jan–Sep) | 2024 Per-Capita Rate | Year Direction |
|---|---|---|---|
| British Columbia | Largest single share | High; ≥20 per 100,000 | ↓ Decreased 2023→2024 |
| Alberta | Second largest share | ≥20 per 100,000 | ↓ Decreased 2023→2024 |
| Ontario | Third largest share (near AB) | High absolute numbers | ↓ 17% preliminary decrease 2023→2024 |
| BC + Alberta + Ontario combined | 78% of all deaths (Jan–Sep 2025) | — | All three decreased 2024 |
| Yukon | Small absolute number | Highest per-capita nationally | Elevated per capita |
| Manitoba | Moderate absolute | ≥20 per 100,000 (2024) | ~No change 2023→2024 |
| Saskatchewan | Moderate | High; elevated western pattern | Part of western cluster |
| Quebec | Significant absolute | Rising trajectory pre-2024 | ↓ Began decreasing 2024 |
| Nova Scotia | Lower absolute | Moderate | Atlantic pattern |
| New Brunswick | Lower absolute | Moderate | Atlantic pattern |
| PEI | Very small; suppressed | Suppressed (small sample) | — |
| Newfoundland & Labrador | Small | Moderate | — |
| Northwest Territories | Small | Elevated per-capita | Remote access challenges |
| 12 provinces/territories | Reporting to PHAC (death data) | — | Most saw decreases 2024 |
Data Sources: PHAC — Key Findings: Opioid- and Stimulant-related Harms in Canada (March 25, 2026); PHAC — Decline in Opioid-related Deaths in Canada (December 11, 2025, with provincial death rate chart data); CBC News — “Overdose Deaths in Canada Fell in 2024” (June 25, 2025) — Yukon, Alberta, Manitoba per-capita ≥20/100K; CCSA/CCENDU — “Recent Trends in Opioid-Related Toxicity Deaths” Issue 6 (August 2025)
The provincial geography of Canada’s opioid crisis has been structurally consistent since national surveillance began in 2016 and reflects deep features of drug supply routing, harm reduction infrastructure distribution, and the socioeconomic conditions that shape vulnerability to substance use disorder. British Columbia has led national attention on the crisis since its April 2016 public health emergency declaration — an emergency now entering its tenth year — and continues to account for the largest single provincial share of opioid toxicity deaths despite years of intensive harm reduction investment. The concentration in BC reflects both a supply-side reality (the province is a major entry point for drug supply moving north from Mexico through the US Pacific Coast corridor) and a harm reduction reality (BC has invested more heavily in supervised consumption, drug checking, and OAT than any other province — investments that are measurably saving lives, but insufficient to overcome the volume and toxicity of what is entering the supply). Alberta’s position at ≥20 deaths per 100,000 population in 2024, despite being the fastest-growing and economically strongest province in Canada, confirms the point made consistently by public health researchers: economic growth and overdose vulnerability are not inversely correlated, and the construction, trades, and energy sector workforce that drives Alberta’s economy carries elevated substance use disorder risk.
Ontario’s preliminary 17% decrease in opioid toxicity deaths from 2023 to 2024 (per Chief Coroner preliminary data cited in CCSA analysis) is encouraging but comes from an extraordinarily high base — Ontario’s large population means even a 17% decline still represents thousands of deaths. The Manitoba finding of approximately no change between 2023 and 2024 is troubling in a year when every other large province showed meaningful declines, and the CCSA Issue 6 report noted this explicitly while cautioning that 2024 Manitoba data should be “interpreted with caution as limitations exist.” The Yukon’s highest-per-capita death rate among all provinces and territories reflects the acute vulnerability of remote, underserved communities where harm reduction access is minimal, where drug supply is highly variable and extremely difficult to check, and where the social determinants of health — housing instability, trauma history, community fracture from the residential school system — are the most severe.
Canada Opioid Crisis — Hospitalizations, ED Visits, and EMS Responses 2026
Non-Fatal Opioid Harms — Healthcare System Impact (PHAC, 2024–2025)
(PHAC Dashboard March 25, 2026; CIHI hospitalization data)
CUMULATIVE (2016–Sep 2025):
Hospitalizations: 51,563 opioid-related poisoning hospitalizations
ED Visits: (national; tracked from 2016)
EMS Responses: (national; tracked from 2016)
FULL YEAR 2024 (vs 2023 — all ~15% lower):
Hospitalizations: 5,514 ↓ −15% from 2023
ED Visits: 24,587 ↓ ~−15%
EMS Responses: 36,266 ↓ ~−15%
2025 (Jan–Sep):
Hospitalizations: 3,613 69% accidental
ED Visits: Preliminary Stabilized (not further declining)
EMS Responses: Stabilized in H1 2025 per Council of CMOHs statement
HOSPITALIZATION PROFILE (Jan–Sep 2025):
Male: 58% | Female: 42% — narrower gender gap than for deaths (74% male)
Age 60+: 27% of hospitalizations — overrepresented relative to deaths
Fentanyl/analogues involved: 24% of hospitalizations
Also involved stimulant: 16% of hospitalizations
Accidental: 69% of hospitalizations
| Non-Fatal Harm Metric | 2024 Full Year | Jan–Sep 2025 | Change 2023→2024 |
|---|---|---|---|
| Opioid poisoning hospitalizations | 5,514 | 3,613 | −15% from 2023 |
| Emergency department visits | 24,587 | Preliminary — stabilized | ~−15% from 2023 |
| EMS responses to suspected overdoses | 36,266 | Stabilized (H1 2025) | ~−15% from 2023 |
| Cumulative hospitalizations (2016–Sep 2025) | — | 51,563 | — |
| Hospitalization gender — male (2025 Jan–Sep) | — | 58% | Narrower than deaths gap |
| Hospitalization gender — female | — | 42% | Higher female share than deaths |
| Age 60+ share of hospitalizations | — | 27% — largest single age group | Overrepresented vs. deaths |
| Fentanyl / analogues in hospitalizations | — | 24% of cases | Increased 50% since 2018 |
| Stimulants also involved (hospitalizations) | — | 16% of cases | Lower than for deaths |
| Accidental hospitalizations | — | 69% | 27% points lower than for deaths |
| Provinces with hospitalization data | — | 11 provinces/territories | Quebec excluded |
| ED visit provinces with data | — | 7 provinces/territories | Partial national picture |
Data Sources: PHAC — Key Findings: Opioid- and Stimulant-related Harms in Canada (March 25, 2026 update); GlobalNews — June 25, 2025 (2024 hospitalization/ED/EMS figures); PHAC — Decline in Opioid-related Deaths (December 11, 2025); Council of Chief Medical Officers of Health Statement (December 11, 2025)
The non-fatal harm statistics for Canada’s opioid crisis provide a fuller picture of the public health system burden than death counts alone reveal. For every person who died from an opioid-related poisoning in Canada in 2024, approximately 0.77 people were hospitalized, 3.44 people visited an emergency department, and 5.07 people required an EMS response — creating a ratio of approximately 1 death : 1 hospitalization : 3.4 ED visits : 5 EMS calls in the 2024 data. This cascade of harm represents a massive ongoing burden on emergency healthcare infrastructure at every level, and the 15% across-the-board decline in all four harm metrics between 2023 and 2024 — deaths, hospitalizations, ED visits, and EMS responses all falling in roughly equal proportion — provides strong evidence that the 2024 improvement was a genuine, broad-based reduction in crisis events rather than a statistical artifact of measurement changes in any single indicator. The stabilization of hospitalizations and EMS responses in the first half of 2025, however, despite continued death decline, raises the important clinical question of whether the death decline reflects improved survival from overdose events (better naloxone access, faster EMS response) rather than simply fewer overdose events occurring.
The hospitalization demographic profile diverges meaningfully from the death profile in ways that carry significant clinical and policy implications. While 74% of opioid toxicity deaths in 2025 involve males, only 58% of opioid poisoning hospitalizations involve males — a narrower gender gap that reflects higher female rates of survival from overdose events and/or higher female rates of seeking or receiving medical care following near-fatal overdose. The 27% of hospitalizations involving people aged 60 and older — contrasted with the 30–39 age group that dominates deaths — reflects a different pattern of opioid exposure: older Canadians who are hospitalized are more likely to be experiencing pharmaceutical opioid complications (prescription pain management, long-term opioid therapy) rather than illegal drug toxicity, and their hospitalizations reflect a different dimension of the opioid crisis that intersects with pain management policy, chronic disease, and the overprescription legacy of the early 2010s. The 24% of hospitalizations involving fentanyl or analogues — lower than the 58–74% fentanyl share of deaths — confirms that fentanyl is disproportionately lethal relative to other opioids: it kills before hospitalization occurs, rather than after it.
Canada Opioid Crisis — Drugs Involved and Emerging Threats 2026
Drugs Involved in Canadian Opioid Toxicity Deaths — Key Shifts
(PHAC Dashboard March 25, 2026; Health Canada Drug Analysis Service; PHAC research publications)
FENTANYL SHARE OF OPIOID DEATHS:
2016: ~53% |████████████████████████████████
2019: ~67% |████████████████████████████████████████
2021: ~86% |███████████████████████████████████████████████████████ ← Peak fentanyl share
2024: ~74% |██████████████████████████████████████████████
Jan–Sep 2025: 58% |████████████████████████████████████
STIMULANT CO-INVOLVEMENT (cocaine, methamphetamine, amphetamines):
2018: ~31% of opioid deaths
Jan–Sep 2025: 70% of opioid deaths ← More than doubled since 2018
EMERGING THREATS DOCUMENTED IN PHAC PUBLICATIONS (2025–2026):
Nitazenes: Detected in opioid toxicity deaths 2020–2024; PHAC report published Dec 2025
Xylazine: Veterinary tranquilizer; PHAC Xylazine report published Dec 2025
Medetomidine: Veterinary sedative; NOT reversed by naloxone; 2025 detections rising
Para-fluorofentanyl: Fentanyl analogue; 57% of deaths in Jan–Sep 2025 involve analogues
Benzodiazepines: Decreased in 2024–25 supply; previously major contributor to deaths
| Drug / Substance Category | 2025 Involvement in Deaths (Jan–Sep) | Trend | Clinical Concern |
|---|---|---|---|
| Fentanyl | 58% of opioid toxicity deaths | ↓ Declining from 86% (2021) | Still #1 identified drug; partially reversed by naloxone |
| Fentanyl analogues (para-fluorofentanyl, acetylfentanyl, etc.) | 57% of deaths | Growing role | Variable naloxone response |
| Any stimulant (cocaine, methamphetamine) | 70% of deaths | ↑ Growing sharply from 31% in 2018 | Cardiac arrest mechanism; naloxone ineffective for stimulant component |
| Cocaine (specific stimulant) | Largest stimulant category | ↑ Rising | Combined cardiovascular + respiratory failure |
| Methamphetamine | Second stimulant category | ↑ Rising in Prairie provinces | BC/AB/Manitoba data particularly prominent |
| Non-pharmaceutical opioids | 81% of all deaths | Consistently dominant since 2020 | Illegal supply; variable composition |
| Nitazenes (new synthetic opioid class) | Detected 2020–2024; PHAC report | ↑ Increasing detections | Ultra-potent; different receptor binding; challenging reversal |
| Xylazine (veterinary sedative) | Detected; PHAC Xylazine report Dec 2025 | Emerging | Skin necrosis; NOT reversed by naloxone alone |
| Medetomidine (veterinary sedative) | Detected multiple provinces 2025 | Emerging; rising | NOT reversed by naloxone |
| Benzodiazepines (illicit) | Decreased in 2024–25 | ↓ Declining — key factor in death reduction | Previously major driver of fatal polydrug toxicity |
| Carfentanil (fentanyl analogue) | Less frequent than 2021–22 | ↓ Decreasing in most regions | Still extremely potent; occasionally detected |
| Pharmaceutical opioids (oxycodone, hydromorphone, morphine) | Minor share of street deaths | Stable/small | Pharmaceutical misuse context |
Data Sources: PHAC — Key Findings: Opioid- and Stimulant-related Harms in Canada (March 25, 2026); Health Canada — “Data, Surveillance and Research on Opioids” — specific publication listing “Nitazenes in Apparent Opioid Toxicity Deaths in Canada, 2020 to 2024” and “Xylazine in Apparent Drug Toxicity Deaths in Canada, 2019 to 2024” (canada.ca, December 2025); PHAC — Decline in Opioid-related Deaths (December 11, 2025); Council of Chief Medical Officers of Health Statement (December 11, 2025); CCSA/CCENDU — Issue 6 (August 2025)
The evolving drug composition of Canada’s opioid crisis is arguably the most clinically significant and rapidly changing dimension of the entire emergency in 2026. The rise of stimulant co-involvement from 31% of opioid deaths in 2018 to 70% in 2025 represents one of the most dramatic shifts in the crisis’s pharmacological character. This is not simply a matter of more people using both cocaine and opioids simultaneously: it reflects a deliberate or incidental contamination of drug supplies and a pattern of drug use in which cocaine, methamphetamine, and synthetic opioids are consumed together — sometimes knowingly, often unknowingly — creating death scenarios that involve simultaneous respiratory depression (the opioid effect) and cardiac complications (the stimulant effect). This combination is particularly dangerous because naloxone reverses the opioid component only: a person revived from respiratory depression by naloxone may still experience fatal cardiac arrest from the stimulant. The Council of Chief Medical Officers of Health explicitly noted this dynamic in their December 2025 statement, flagging “rising benzodiazepine and cocaine presence” as one of several supply changes presenting ongoing challenges even as fentanyl concentrations have partially declined.
The emergence of nitazenes and xylazine as documented threats in the Canadian drug supply — both now the subject of dedicated PHAC research publications released in December 2025 — represents the newest and most alarming frontier of the crisis. Nitazenes are a class of ultra-potent synthetic opioids with a completely different chemical structure from fentanyl and other traditional opioids; some are estimated to be 10 to 100 times more potent than fentanyl itself. They were originally developed as potential analgesics in the 1950s but never approved for human use, and their appearance in the illegal drug supply — confirmed in PHAC’s “Nitazenes in Apparent Opioid Toxicity Deaths in Canada, 2020 to 2024” publication — means the supply is diversifying beyond fentanyl and its analogues into entirely different molecular territory. Xylazine, the veterinary tranquilizer that has produced a parallel crisis in the US “tranq” drug supply, has similarly been documented in Canadian drug toxicity deaths through PHAC’s “Xylazine in Apparent Drug Toxicity Deaths in Canada, 2019 to 2024” publication. Like medetomidine, xylazine is not reversed by naloxone and causes severe dermal necrotic wounds in people who inject it — a clinical presentation that requires wound care in addition to overdose management. The Canadian drug supply in 2026 is more chemically complex, more naloxone-resistant in some components, and more diverse in its lethal mechanisms than at any point since the crisis began in 2016.
Indigenous Peoples and the Opioid Crisis in Canada 2026
Indigenous Peoples — Disproportionate Opioid Crisis Impact
(Chiefs of Ontario / ODRPN Oct 2025; FNHA 2024; Statistics Canada; PHAC)
First Nations in Ontario — opioid death rate vs. non-First Nations (2022):
First Nations: 12.8 deaths per 10,000 people
Non-First Nations: 1.4 deaths per 10,000 people
Ratio: 9× HIGHER — up from 3× in 2019 (TRIPLED in 3 years)
2021 + 2022 combined: 389 First Nations people died of overdose in Ontario
Indigenous people (general) vs. non-Indigenous:
Up to 6× more likely to experience opioid-related harm (FNHA 2024)
First Nations on reserve (Statistics Canada): 5.6× higher hospitalization rate
In Alberta (2020 data):
First Nations = 22% of opioid poisoning deaths despite being ~6% of population
Rate: 7× higher for First Nations vs. non-First Nations
| Indigenous Population Metric | Figure | Source |
|---|---|---|
| First Nations in Ontario — opioid death rate (2022) | 12.8 per 10,000 vs. 1.4 non-First Nations | Chiefs of Ontario / ODRPN (October 6, 2025) |
| Ratio: First Nations vs. non-First Nations death rate (Ontario 2022) | 9× higher | Chiefs of Ontario / ODRPN (October 6, 2025) |
| Death rate increase for First Nations in Ontario (2019→2022) | Tripled in 3 years | Chiefs of Ontario / ODRPN (October 6, 2025) |
| First Nations people who died of overdose in Ontario (2021 + 2022) | 389 people | Chiefs of Ontario / ODRPN (October 6, 2025) |
| Indigenous peoples vs. non-Indigenous: opioid harm likelihood | Up to 6× more likely | First Nations Health Authority, 2024 (cited CPHA) |
| First Nations on-reserve hospitalization rate vs. non-Indigenous | 5.6× higher | Statistics Canada (2011–2016 data, cited Library of Parliament) |
| Métis opioid hospitalization rate vs. non-Indigenous | 3.2× higher | Statistics Canada (cited Library of Parliament) |
| Inuit opioid hospitalization rate vs. non-Indigenous | 3.2× higher | Statistics Canada (cited Library of Parliament) |
| Alberta First Nations share of opioid deaths (H1 2020) | 22% of deaths; ~6% of population | AB First Nations Information Governance Centre / AB Health |
| Alberta First Nations death rate vs. non-First Nations | 7× higher | AB First Nations Information Governance Centre / AB Health |
| Root cause acknowledged by CCMOH | “Intergenerational impacts of colonization and systemic racism” | Council of Chief Medical Officers of Health (December 11, 2025) |
| Federal funding for Indigenous health/wellness | $2 billion over 10 years + $650 million (2024–25) | Health Canada — Federal Actions overview |
Data Sources: Chiefs of Ontario / Ontario Drug Policy Research Network — “First Nations People in Ontario Disproportionately Affected by Opioid Crisis” (October 6, 2025); First Nations Health Authority — cited in Canadian Public Health Association Toxic Drug Crisis page (2024); Statistics Canada hospitalization data cited in Library of Parliament — “The Opioid Crisis in Canada” (lop.parl.ca); Alberta First Nations Information Governance Centre / Alberta Health (2020 data cited in Library of Parliament); Council of Chief Medical Officers of Health Statement (December 11, 2025); Health Canada — “Federal Actions on the Overdose Crisis” (canada.ca)
The disproportionate impact of the opioid crisis on Indigenous peoples in Canada is one of the most consistently documented and most inadequately addressed dimensions of the entire emergency. The 9-fold higher opioid death rate for First Nations people in Ontario compared to non-First Nations in 2022 — confirmed in the October 2025 report by the Chiefs of Ontario and the Ontario Drug Policy Research Network — is not a recent anomaly but the product of a tripling of the death rate in just three years (2019 to 2022), suggesting that the crisis has deepened its grip on First Nations communities even as national-level trends have partially improved. The 389 First Nations people who died of overdose in Ontario in 2021 and 2022 alone represents an enormous toll from a community that makes up a small fraction of the provincial population. In Alberta, First Nations people accounted for 22% of all opioid poisoning deaths in the first half of 2020 despite comprising approximately 6% of the province’s population — a seven-fold overrepresentation that reflects the compounding effects of geographic isolation, historical trauma, and systemic underinvestment in culturally appropriate healthcare.
The Council of Chief Medical Officers of Health explicitly named “intergenerational impacts of colonization and systemic racism” as the root cause of Indigenous peoples’ disproportionate exposure in their December 2025 national statement — a rare and important formal acknowledgment from the country’s highest public health leadership that the crisis cannot be addressed through pharmacological or harm reduction interventions alone. The federal government has committed $2 billion over 10 years for Indigenous health initiatives through the Working Together for Health Care agreements, and an additional $650 million over two years (2024–2025) toward “trauma-informed, culturally grounded, community-based mental wellness initiatives” that specifically include Indigenous communities. These investments are meaningful in scale, but the Chiefs of Ontario report explicitly called for collaboration between provincial and federal governments and First Nations to develop “a comprehensive strategy that shifts focus from punitive measures towards culturally sensitive and spiritually informed supports” — framing that positions the current response as necessary but insufficient, and the system as still requiring fundamental reorientation toward Indigenous-led, community-based approaches.
Canada’s Federal Response — Funding, Harm Reduction and Policy 2026
Federal Financial Commitments — Canada's Opioid Crisis Response
(Health Canada — "Federal Actions on the Overdose Crisis"; canada.ca, accessed May 2026)
$25 billion ████████████████████████████████████████████ Working Together for Health Care
(mental health + substance use services; provinces/territories)
$2 billion ████████████████ Indigenous health initiatives (10 years)
$758 million+ ████████████ Substance Use and Addiction Program (SUAP)
465+ community pilot projects since 2017
$650 million ████████████ Trauma-informed mental wellness (2024–25, 2 years)
Includes Indigenous community initiatives
$500 million ██████████ Youth Mental Health Fund
$72.1 million ████ Veteran Homelessness Program
$20.2 million ███ Youth Substance Use Prevention Program
Emergency order (2025):
3 fentanyl precursor chemicals rapidly controlled
China engagement to stop precursor shipments
1,000 new CBSA officers + 1,000 new RCMP officers
| Federal Action / Program | Investment / Detail | Status |
|---|---|---|
| Working Together for Health Care agreements | $25 billion — mental health + substance use | Active; 10-year commitment |
| Indigenous health initiatives | $2 billion over 10 years | Active |
| Substance Use and Addiction Program (SUAP) | $758 million+ / 465+ community projects since 2017 | Active; new Call for Proposals Nov 2025 |
| Trauma-informed mental wellness | $650 million (2024–2025, 2 years) | Active |
| Youth Mental Health Fund | $500 million | Active |
| Veteran Homelessness Program | $72.1 million — rent supplements + services | Active |
| Youth Substance Use Prevention | $20.2 million / 13 community projects | Active |
| Know More Opioids youth program | 201,628 students reached since 2018 | Active |
| Festival outreach (naloxone/overdose info) | 2,200+ festival organizers reached in 2025 | Active |
| Emergency precursor chemical order (2025) | 3 fentanyl precursors rapidly scheduled | New; operational |
| China engagement — precursors | Government-to-government action on precursor shipments | Active |
| Naloxone distribution | Hundreds of thousands of kits distributed in 2024 | Active; national |
| New CBSA personnel | 1,000 new officers — border enforcement | Committed; being deployed |
| New RCMP personnel | 1,000 new officers — community safety | Committed |
| Supervised consumption sites | Operating: BC, Alberta (contested), Ontario (contested) | Active; politically contested |
| OAT (methadone, buprenorphine) | Expanded access program — multiple provinces | Active |
| Precursor Chemicals Risk Management Unit | New Health Canada unit; enhanced surveillance | Established 2025 |
| BC Public Health Emergency | Still in force since April 2016 | 10th year; ongoing |
Data Sources: Health Canada — “Federal Actions on the Overdose Crisis” (canada.ca, updated and accessed May 2026); PHAC — Decline in Opioid-related Deaths (December 11, 2025); Council of Chief Medical Officers of Health Statement (December 11, 2025); CBSA — Operation Blizzard announcement (February 27, 2025); Government of Canada — Border Security Actions (canada.ca)
Canada’s federal financial commitment to the opioid crisis is substantial in scale — the combination of the $25 billion Working Together for Health Care agreements (allocated toward mental health and substance use services), the $758 million+ Substance Use and Addiction Program, and targeted spending on Indigenous health, youth prevention, and trauma-informed care represents one of the largest sustained public health investments in Canadian history. The 465+ innovative community-based pilot projects funded through SUAP since 2017 cover the full spectrum of harm reduction approaches — medication-assisted therapies, OAT programs, stigma reduction, safe supply pilot programs, naloxone distribution, and community education — and a new Call for Proposals closed in November 2025 will fund a further wave of projects beginning as early as April 2026. The Know More Opioids youth awareness program reaching 201,628 students since April 2018 and the naloxone festival outreach to more than 2,200 festival organizers in 2025 reflect the federal government’s recognition that prevention and community presence require consistent outreach well beyond the clinical setting.
The December 2025 emergency scheduling of three fentanyl precursor chemicals and the commitment to engage China to stop precursor shipments address the supply-side root of the crisis in a way that law enforcement seizures alone cannot: if the chemicals needed to synthesize fentanyl and its analogues can be controlled earlier in the chain, the manufacturing capacity of criminal networks is directly constrained. The Health Canada Precursor Chemicals Risk Management Unit established in 2025 institutionalizes this approach, combining surveillance, regulation, and enforcement in a dedicated structure that coordinates with international partners. Whether this supply-side pressure translates into sustained reductions in drug supply toxicity remains to be seen — the criminal networks producing synthetic opioids have historically proven adept at switching between precursor chemicals and synthetic pathways when any single input is controlled. What the December 2025 Council of Chief Medical Officers of Health statement makes clear is that no single intervention — not naloxone, not OAT, not supply interdiction, not safe supply — is sufficient on its own, and that “prevention, education, treatment, recovery, and harm reduction are all critical pieces of a response that reduces mortality and connects people to care” — a statement of coordinated action that the uneven, politically contested nature of Canada’s provincial-level response has yet to fully match in practice.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
